Hodgkin's Lymphoma Incidence Rates
In medicine–in this case oncology–the "incidence rate" is the number of new disease cases that will occur in a given population.
According to the Leukemia and Lymphoma Society, Hodgkin's Lymphoma represents about 11% of all lymphoma diagnoses. Approximately 8,000 cases (4,400 males and 3,820 females) of Hodgkin's Lymphoma are detected per year which represents less than 1% of all cancers. Nevertheless, this is a still a significant disease worldwide and incidents are on the rise.
Selected Hodgkin's Incidence Statistics
From The National Cancer Institute's SEER program. Numbers are based on cases diagnosed in 2002-2006 from 17 SEER geographic areas.
Median age at diagnosis: 64 years
3.0% were diagnosed under age 20; 7.5% between 20 and 34; 8.4% between 35 and 44; 13.7% between 45 and 54; 17.8% between 55 and 64; 20.4% between 65 and 74; 21.4% between 75 and 84; and 7.8% 85+ years of age.
Incidence Rates by Race/Gender
Men
- All Races: 26.6 per 100,000 men
- White: 27.7 per 100,000 men
- Black: 21.2 per 100,000 men
- Asian/Pac Islander 17.0 per 100,000 men
- American Indian/Alaska Native: 12.9 per 100,000 men
- Hispanic: 22.0 per 100,000 men
Women
- All Races: 18.9 per 100,000 women
- White: 19.8 per 100,000 women
- Black: 14.5 per 100,000 women
- Asian/Pacific Islander: 12.0 per 100,000 women
- American Indian/Alaska Native 10.7 per 100,000 women
- Hispanic: 16.5 per 100,000 women
More data can be found on the SEER page for Hodgkin's Lymphoma.
Resources
- U.S. Cancer Statistics from the CDC
- Ries LAG, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (eds). SEER Cancer Statistics Review, 1973-1996, National Cancer Institute. Bethesda, MD, 1999.
- US National Cancer Institute SEER Data - Hodgkin's Lymphoma
- American Cancer Institute - Key Statistics for Hodgkin's Disease
- The (US) Leukemia & Lymphoma Society - Hodgkin Lymphoma
- Cancer Research UK - Statistics and prognosis of Hodgkin's lymphoma
- MedlinePlus - Hodgkin's Disease
Further Reading
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
